Company
Business
Stem Cell Therapy
Organoid
CDMO Business
Press Release
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Kangstem Biotech Appoints Founder Kyung-Sun Kang, Professor at Seoul National University, as CSO(Chief Scientific Officer)
03
2026.08
- Enhancing Science-driven management across R&D, clinical development and commercialization to accelerate the company’s growth into a global biotech leader
Kangstem Biotech announced on August 3 that it has appointed Professor Kyung-sun Kang of the College of Veterinary Medicine at Seoul National University, the company's founder and current Technical Advisor, as its Chief Scientific Officer (CSO).
The appointment is intended to further strengthen the company's research and development capabilities based on its stem cell and organoid platform technologies while advancing its global business development and clinical development strategies. As CSO, Professor Kang will oversee the company's R&D, clinical development strategy, pipeline planning, advancement of its organoid platform, and acquisition of next-generation technologies. He will also lead the company's long-term technology vision and research direction.
Professor Kang has been actively conducting research as a faculty member at Seoul National University and is widely recognized as one of Korea's leading scientists in stem cell research and regenerative medicine. He founded Kangstem Biotech and laid the foundation for the company's stem cell therapy development, establishing himself as a pioneering figure in the field of regenerative medicine in Korea. In recognition of his outstanding research achievements, he was recently selected for the "Top 30 Outstanding R&D Achievements in Healthcare" by Korea's Ministry of Health and Welfare, further earning recognition from both academia and industry.
With Professor Kang's appointment as CSO, the company plans to establish a "Science-Driven Company" framework that more closely integrates scientific research with business development while strengthening its pipeline strategy with a focus on global licensing opportunities. His scientific expertise will also play a key role in shaping the clinical development and commercialization strategies of the company's major pipeline programs, including OSCA, its investigational treatment for knee osteoarthritis, and its organoid-based drug evaluation platform.
Professor Kang commented, "Since its founding, Kangstem Biotech has pursued the vision of becoming a global stem cell platform company. As CSO, I will work to further integrate research and clinical development to deliver innovative therapeutic technologies to patients while continuously creating technologies and products that gain recognition in the global market."
CEO Jong-cheon Na stated, "Professor Kang's appointment as Chief Scientific Officer marks an important milestone in further enhancing the company's scientific competitiveness. By combining the founder's scientific vision with the company's commercialization capabilities, we will accelerate global licensing, strategic partnerships, and new drug development while continuing to enhance shareholder value."